Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

T-039

Supelco

Topiramate solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C12H21NO8S
Número de CAS:
97240-79-4
Peso molecular:
339.36
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

InChI key

KJADKKWYZYXHBB-XBWDGYHZSA-N

Gene Information

human ... CA2(760) , CA4(762) , GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879) , GRIA1(2890) , GRIA2(2891) , GRIA3(2892) , GRIA4(2893) , GRIK1(2897) , GRIK2(2898) , GRIK3(2899) , GRIK4(2900) , GRIK5(2901) , SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

General description

A certified solution standard suitable for use in LC/MS or GC/MS applications for pharmaceutical research, clinical toxicology, or forensic testing.  Topiramate, sold under trade name Topamax®, is an antiepileptic drug used for treatment of seizures. Topiramate in combination with the stimulant phentermine constitute the active compounds in the new weight lose drug Qsymia®.

Application


  • Topiramate research solution: Research focuses on the development of intravenous formulations of topiramate for rapid intervention in seizure emergencies, highlighting its potential in emergency medicine and critical care (Epilepsy Behav, 2023; doi: 10.1016/j.yebeh.2023.109158).

  • Topiramate liquid formulation: Innovations in drug delivery include the use of topiramate-chitosan nanoparticles, which offer enhanced drug stability and targeted delivery, particularly in addiction treatment settings (Neurochem Int, 2021; doi: 10.1016/j.neuint.2021.105157).

  • Anticonvulsant biochemical reagent: Topiramate′s role as an anticonvulsant is further explored in studies focusing on its pharmacokinetic properties and interaction with other medications, emphasizing its importance in personalized medicine (Ther Drug Monit, 2019; doi: 10.1097/FTD.0000000000000600).

  • Topiramate in vitro study: The compound is utilized in in vitro setups to investigate its effects on neuronal excitability, providing insights into its mechanism of action and potential therapeutic applications (Epilepsia, 2019; doi: 10.1111/epi.16073).

  • Topiramate pharmacological research: Studies include the development of advanced analytical methods for the quantification of topiramate in biological samples, supporting its clinical monitoring and therapeutic drug management (J Pharm Biomed Anal, 2015; doi: 10.1016/j.jpba.2015.01.035).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Qsymia is a registered trademark of Vivus, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Topamax is a registered trademark of Johnson & Johnson

related product

Referencia del producto
Descripción
Precios

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk_germany

WGK 1

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 3

1 of 3

Valproic acid solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

V-006

Valproic acid solution

Primidone analytical standard

Supelco

P7295

Primidone

Itraconazole ≥98% (HPLC)

Sigma-Aldrich

I6657

Itraconazole

J M Riffitts et al.
Journal of pharmaceutical and biomedical analysis, 19(3-4), 363-371 (2000-03-07)
An accurate and robust method involving liquid liquid extraction and capillary gas chromatographic (GC) assay with nitrogen phosphorus detection (NPD) was developed and validated for the quantitative determination of topiramate [2,3:4,5-bis-O-(-1-methylethylidene)-beta-D-fructopyranose sulfamate], Topamax, an anticonvulsant drug, in human plasma, urine
Steve S Chung et al.
Epilepsia, 55(7), 1077-1087 (2014-06-07)
To evaluate the efficacy and safety of USL255, Qudexy(™) XR (topiramate) extended-release capsules, as an adjunctive treatment for refractory partial-onset seizures (POS) in adults taking one to three concomitant antiepileptic drugs. In this global phase III study (PREVAIL; NCT01142193), 249
William Timothy Garvey
Expert opinion on drug safety, 12(5), 741-756 (2013-06-07)
Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction
Elizabeth M Kelly et al.
Journal of managed care pharmacy : JMCP, 19(8), 642-654 (2013-10-01)
Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight
Annie M Clark et al.
Epilepsia, 55(7), 1069-1076 (2014-05-28)
Evaluate the pharmacokinetics (PK), safety, and tolerability of single doses of once-daily USL255, Qudexy XR (topiramate) extended-release capsules, over a wide dosing range. Two single-dose, phase I studies in healthy adults were used to evaluate the PK profile and maximum
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico